Nurix Therapeutics (NRIX)

Executive Summary

Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) to treat cancer and autoimmune diseases. Its proprietary platforms—including degraders and Deubiquitinase Targeting Chimeras (DACs)—modulate cellular protein levels by harnessing the body’s natural degradation systems. The company’s lead asset, NX-5948, is a potent, oral BTK degrader in Phase 1/2 trials for chronic lymphocytic leukemia (CLL) and other B-cell malignancies, with a Phase 2 study initiated in late 2025. Another key program, NX-2127, is an oral BTK degrader in Phase 1 for relapsed/refractory B-cell cancers, while NX-1607 targets CBL-B in multiple solid tumors as a single agent and in combination with checkpoint inhibitors or chemotherapy. With a market capitalization of approximately $1.7 billion, Nurix has advanced multiple candidates into the clinic, demonstrating proof-of-concept for its TPD approach. Upcoming value-driving milestones include interim data from the NX-5948 Phase 2 expansion in CLL, dose-escalation results from NX-2127, and combination data from NX-1607. Near-term catalysts could significantly de-risk the pipeline and position Nurix as a leader in protein degradation therapeutics. The company benefits from a strong cash position (over $500 million as of mid-2026) to fund operations into 2028.

Upcoming Catalysts (preview)

• H2 2026Phase 2 interim data for NX-5948 in CLL60% success
• 2026Phase 1 dose-expansion data for NX-2127 in B-cell malignancies55% success
• 2026Phase 1b combination data for NX-1607 in solid tumors45% success